Abstract
It is quite apparent to me that very few people understand the meaning of the word “epistemology”. It may be difficult to pronounce but it is quite easy to understand. Epistemology is the study of the growth of knowledge, or “how do we know what we think we know”? What I would now like to try to get across is that scientific philosophy is not a rarefied activity indulged in by retired physicians who have nothing better to do with the remainder of their lives; rather, it is a very important aspect of medical education and medical practice. I will illustrate this by describing aspects of the growth of philosophy and how this has an impact on our everyday practice. I would like to start off with Aristotle, the Greek philosopher who was the father of inductivism. Inductivism is another word that is frequently used but not clearly understood. Simply put, inductivism is the process by which you generate a hypothesis and then seek corroborative evidence to prove that your hypothesis is an expression of the truth. The history of medicine is littered with the tragic failures of this philosophical approach. Galen, a second-century physician, was the master of inductivism in medical practice and his malign influence led to 1600 years of sterility. This sterility was not merely an inhibition of medical progress; it also included the perpetuation of barbaric and useless treatments such as that of bleeding and cupping, the panacea approaches for most ills up until the early years of the past century. To this day, you will meet contemporary inductivists pacing the marble corridors of ultramodern high-technology hospitals, introducing and perpetuating dangerous therapies without having the intellectual honesty to seek anything other than corroborative evidence in support of their ideas. I would now like to take you 1000 years further, to the birth of the deductive process in medical science. William of Okam was a thirteenth-century English monk, and his famous aphorism “Entiae non multiplicandum necessitatum” describes the philosophical underpinning of the modern approach to medical diagnosis. A loose translation of the Latin would be that on observing multiple phenomena you should try to explain your observations in terms of the simplest underlying cause. Thus, the whole process of diagnosis is the eliciting of symptoms and signs from the patient, and instead of coming up with multiple explana- tions for them we apply Okam’s razor to postulate a single causal explanation with multiple epiphenomena.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baum M (1983) Quack cancer cures or scientific remedies? Clin Oncol 9: 275–280
Berstock DA, Houghton J, Haybittle J, Baum M (1985) The role of radiotherapy following total mastectomy for patients with early breast cancer. World J Surg 661–670
Bonadonna G, Valagusa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 30: 10–15
Breasted JH (1930) The Edwin Smith papyrus. University of Chicago Press, Chicago, pp 403–406
Cade Sir S (1948) Discussion: the treatment of cancer of the breast. Proc R Soc Med 41:129
Cole MP (1970) Prophylactic compared with therapeutic X-ray artificial menopause, 2nd Tenovus Workshop on Breast Cancer. Alpha-Omega, Cardiff, pp 2–11
Cuzick J, Baum M (1985) Tamoxifen and contralateral breast cancer. Lancet ii: 282
Cuzick J, Wang DY, Bulbrook RD (1986) The prevention of breast cancer. Lancet i: 83–86
De Moulin D (1983) In: A short history of cancer. Nyhoff, Boston
Dunn AR (1986) Viral and cellular oncogenes a molecular basis for breast and other cancers. In: Forbes JF (ed) Breast disease, vol 5. Churchill Livingstone, Edinburgh, pp 59–68
Fallowfield L, Baum M, Maguire GP (1986) The effects of breast conservation on the psychological morbidity associated with the diagnosis and treatment of early breast cancer. Br Med J (In press)
Fisher B (1970) The surgical dilemma in the primary therapy of invasive breast cancer. A critical appraisal. In: Current problems in surgery. Year Book Publishers, Chicago
Fisher B, Redmond C, Fisher ER (1980) The contribution of recent NSABP trials of primary breast cancer therapy to an understanding of tumour biology. Cancer 46: 1009
Goldhirsch A, Gelber RD, Davis BW (1986) Adjuvant chemotherapy trials in breast cancer: an appraisal and lessons for patient care outside the trials. In: Forbes JF (ed) Breast disease, vol 10. Churchill Livingstone, Edinburgh, pp 123–138
Gross SW (1880) A practical treatise of tumours of the mammary gland. Appleton, New York
Halsted WS (1898) The radical operation for the cure of carcinoma of the breast. Johns Hopkins Hospital reports, no 28, p 557
Keynes G (1937) Conservative treatment of cancer of the breast. Br Med J 643–647
Kon OL (1983) An antiestrogen-binding protein in human tissues. J Biol Chem 258: 3173
Lippman ME, Bolan G (1975) Oestrogen-responsive human breast cancer in long-term tissue culture. Nature 256: 592–593
Maguire P (1982) Psychiatric morbidity associated with mastectomy. In: Baum M, Kay R, Scheurlen H (eds) Clinical trial in early breast cancer, 2nd Heidelberg symposium. Birk-häuser, Basel, pp 373–380
Meyer JS, Rao BR, Stevens SC, White WL (1977) Low incidence of oestrogen receptors in breast carcinoma with rapid rates of cellular replication. Cancer 40: 2290
Nolvadex Adjuvant Trial Organisation (NATO) (1983) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Interim analysis at 4 years by NATO. Lancet i: 257–261
Nolvadex Adjuvant Trial Organisation (NATO) (1985 a) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at 6 years by NATO. Lancet i:836–840
Nolvadex Adjuvant Trial Organisation (NATO) (1985 b) Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. World J Surg 9: 756–764
Paterson RP, Russell MH (1959) Clinical trials in malignant disease. J Fac Radiol (Lond) 10:130
Popper KR (1959) The logic of scientific discovery. Hutchinson, London
Rose DP, Davis TE (1977) Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet i: 1174
Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL (1985) Epidermal-growth factor receptors and oestrogen receptors in human breast cancer. Lancet i: 364–366
Steele RJC (1983) Clinical, histological and immunological studies in human breast cancer. MD thesis, University of Edinburgh
Trivedi D (1986) Antigenic profile of human breast tumours. PhD thesis, University of London
UK Breast Cancer Trials Cancer Coordinating Committee/UICC (1984) Review of mortality results in randomised trials in early breast cancer. Lancet ii: 1205
Waterfield MD, Scrace GT, Whittle N, et al (1983) Platelet-derived growth factor is structurally related to the putative transforming protein p28 of simian sarcoma virus. Nature 304: 34
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Baum, M. (1988). Randomised Trials: The Case for Science in Medicine. In: Scheurlen, H., Kay, R., Baum, M. (eds) Cancer Clinical Trials. Recent Results in Cancer Research, vol 111. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83419-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-83419-6_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83421-9
Online ISBN: 978-3-642-83419-6
eBook Packages: Springer Book Archive